Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07815002
PHASE1
Phase I Clinical Study to Evaluate the Safety and Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
View on ClinicalTrials.gov
Summary
This study includes two parts, different part has different administration frequencies of 3SC009.
Official title: Phase I Clinical Study to Evaluate the Safety, Tolerability, and Initial Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-09-30
Completion Date
2028-09-30
Last Updated
2026-09-11
Healthy Volunteers
No
Conditions
Interventions
DRUG
3SC009
A CD47/EpCAM bispecific antibody